Comment on: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the the Danish Head and Neck Cancer Study (DAHNCA) Protocol 5-85
- PMID: 9925257
- DOI: 10.1016/s0167-8140(98)00085-1
Comment on: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the the Danish Head and Neck Cancer Study (DAHNCA) Protocol 5-85
Comment on
-
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.Radiother Oncol. 1998 Feb;46(2):135-46. doi: 10.1016/s0167-8140(97)00220-x. Radiother Oncol. 1998. PMID: 9510041 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical